Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 with Increasing Adoption of Targeted Radiotherapy | DelveInsight

prnewswire.com
LH Lantheus is listed as a key company in the expanding radiopharmaceuticals market, which is driven by increasing chronic illnesses and technological innovations. The company is also mentioned in related reports like Radioligand Therapies and PSMA-targeted Therapy. TH Cardinal Health is mentioned as a key company in the radiopharmaceuticals market, which is experiencing significant expansion. However, the article does not provide specific details on its performance or outlook within this segment. GEHC GE Healthcare is listed as a key player in the growing radiopharmaceuticals market. The article highlights the overall market expansion driven by chronic diseases and technological advancements, but provides no specific sentiment for GE Healthcare. EL Eli Lilly is mentioned in the context of Radioligand Therapies and Prostate Cancer markets, indicating its involvement in growing therapeutic areas within the broader healthcare sector discussed. AZN AstraZeneca is mentioned in the context of Radioligand Therapies and Prostate Cancer markets, indicating its involvement in growing therapeutic areas within the broader healthcare sector discussed. AMGN Amgen is mentioned as a key company in the Prostate Cancer market, which is part of the broader healthcare landscape discussed. However, the article does not provide specific details on its performance or outlook within this segment. PFE Pfizer is mentioned as a key company in the Prostate Cancer market, which is part of the broader healthcare landscape discussed. However, the article does not provide specific details on its performance or outlook within this segment. MRK Merck is mentioned as a key company in the Prostate Cancer market, which is part of the broader healthcare landscape discussed. However, the article does not provide specific details on its performance or outlook within this segment. BMY Bristol Myers Squibb is mentioned as a key company in the Prostate Cancer market, which is part of the broader healthcare landscape discussed. However, the article does not provide specific details on its performance or outlook within this segment. REGN Regeneron is not explicitly mentioned in the article. While it operates in the healthcare sector, its inclusion here would be speculative based on the provided text. GILD Gilead Sciences is not explicitly mentioned in the article. While it operates in the healthcare sector, its inclusion here would be speculative based on the provided text. ABBV AbbVie is not explicitly mentioned in the article. While it operates in the healthcare sector, its inclusion here would be speculative based on the provided text. SNY Sanofi is mentioned as a key company in the Prostate Cancer market, which is part of the broader healthcare landscape discussed. However, the article does not provide specific details on its performance or outlook within this segment. XRAY DENTSPLY SIRONA is not explicitly mentioned in the article. While it operates in the healthcare sector, its inclusion here would be speculative based on the provided text. BRKR Bruker Corporation is mentioned as a key company in the Positron Emission Tomography (PET) market, which is a diagnostic tool within the broader radiopharmaceuticals landscape. The article highlights the market's growth but offers no specific sentiment for Bruker.

Global Radiopharmaceuticals Market Set for Significant Expansion at a CAGR of ~10% by 2034 with Increasing Adoption of Targeted Radiotherapy | DelveInsight The radiopharmaceuticals market is largely propelled by the rising incidence of chronic illnesses, including cancer, cardiovascular diseases, and neurological disorders, which is increasing the need for advanced diagnostic and treatment options. In addition, continuous innovations in imaging technologies, radiotracer design, and theranostic approaches have enhanced diagnostic precision, safety, and overall patient outcomes. Furthermore, improvements in healthcare infrastructure, growing awareness regarding early disease diagnosis, and supportive government policies are encouraging the wider adoption of nuclear medicine procedures.

LAS VEGAS, May 18, 2026 /PRNewswire/ -- DelveInsight's Radiopharmaceuticals Market Insights report provides the current and forecast market analysis, individual leading radiopharmaceuticals companies' market shares, challenges, radiopharmaceuticals market drivers, barriers, trends, and key radiopharmaceuticals companies in the market.

Radiopharmaceuticals Market Summary

To read more about the latest highlights related to the radiopharmaceuticals market, get a snapshot of the key highlights @ https://www.delveinsight.com/sample-request/nuclear-medicine-radiopharmaceuticals-market

Key Factors Contributing to the Rise in Growth of the Radiopharmaceuticals Market

Regional Radiopharmaceuticals Market Insights

North America

Europe

Asia-Pacific

Get a sneak peek at the radiopharmaceuticals market dynamics @ Radiopharmaceuticals Market Trends

Recent Developmental Activities in the Radiopharmaceuticals Market

What are Radiopharmaceuticals?

Radiopharmaceuticals are specialized medicinal formulations that contain radioactive isotopes and are used in both the diagnosis and treatment of diseases, particularly in oncology, cardiology, and neurology. These agents typically consist of a radioactive component (radioisotope) linked to a biologically active molecule that directs the compound to specific organs, tissues, or cellular receptors in the body. Once administered, usually through injection, ingestion, or inhalation, the radiopharmaceutical emits radiation that can either be detected by imaging technologies such as PET (Positron Emission Tomography) and SPECT (Single Photon Emission Computed Tomography) for diagnostic purposes, or deliver targeted radiation to destroy diseased cells in therapeutic applications.

Radiopharmaceuticals Market Report Metrics

Details

Coverage

Global

Study Period

2023–2034

Radiopharmaceuticals Market CAGR

~6%

Radiopharmaceuticals Market Size by 2034

USD 24.1 Billion

Key Radiopharmaceuticals Companies

Lantheus, Cardinal Health, GE Healthcare, Curium Pharma, Pharmalogic Holdings Corp., Novartis, Cambridge Isotope Laboratories, Inc., Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, NECSA Ltd., IBA Radiopharma Solutions, Bayer AG, Norgine, NorthStar Medical Radioisotopes, LLC, Eckert & Ziegler, Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, ROTOP Pharmaka GmbH, and others

Radiopharmaceuticals Market Assessment

Which MedTech key players in the radiopharmaceuticals market are set to emerge as the trendsetter explore @ Radiopharmaceuticals Market Analysis

Table of Contents

1

Radiopharmaceuticals Market Report Introduction

2

Radiopharmaceuticals Market Executive Summary

3

Radiopharmaceuticals Market Key Factors Analysis

4

Impact Analysis

5

Regulatory Analysis

6

Radiopharmaceuticals Market Porter's Five Forces Analysis

7

Radiopharmaceuticals Market Assessment

8

Competitive Landscape

9

Startup Funding & Investment Trends

10

Radiopharmaceuticals Market Company and Product Profiles

11

KOL Views

12

Project Approach

13

About DelveInsight

14

Disclaimer & Contact Us

Interested in knowing the radiopharmaceuticals market share by 2034? Click to get a snapshot of the Radiopharmaceuticals Market Size

Related Reports

Radioligand Therapies Market

Radioligand Therapies Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key RLT companies, including Novartis, Curium Pharma, Lantheus, Eli Lilly and Company, Fusion Pharmaceuticals, AstraZeneca, Clarity Pharmaceuticals, Bayer, ITM Isotope Technologies, ARTBIO, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutic, Nuclidium, and others.

PSMA-targeted Therapy Market

PSMA-targeted Therapy Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key PSMA-targeted therapy companies, including Lantheus, Telix Pharmaceuticals, Novartis, and others.

Prostate Cancer Market

Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key prostate cancer companies, including Sanofi, AstraZeneca, Astellas Pharma, Bayer, Novartis, Curium, Merck, Orion, Janssen Pharmaceutical, Pfizer, Exelixis, Ipsen Pharma, Takeda, AB Science, Lantheus, Eli Lilly, POINT Biopharma, Telix Pharmaceuticals, Tavanta Therapeutics, Jiangsu Hengrui Pharmaceuticals, Kangpu Biopharmaceuticals, Fusion Pharma, Merus, Bristol-Myers Squibb, Syntrix Pharmaceuticals, Promontory Therapeutics, Xencor, Taiho Pharmaceutical, Madison Vaccines, MacroGenics, Zenith Epigenetics, Modra Pharmaceuticals, Arvinas, Laekna Therapeutics, Blue Earth Therapeutics, Oncternal Therapeutics, Essa Pharma, Clarity Pharmaceuticals, BioNTech, DualityBio, Daiichi Sankyo, Fortis Therapeutics, ORIC Pharmaceuticals, Amgen, and others.

Positron Emission Tomography Market

Positron Emission Tomography Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key PET companies, including General Electric Company, Bruker Corporation, Siemens Healthcare GmbH, Koninklijke Philips N.V., Canon Medical Systems Corporation, Positron Corporation, Shimadzu Corp., RefleXion, CMR Naviscan Corporation, Segami Corporation, Neusoft Medical Systems Co., Ltd., Mediso Ltd., Sofie Biosciences (PerkinElmer Inc.), United Imaging Healthcare Co., Ltd., MinFound Medical Systems Co., Ltd, MR Solutions, and others.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Contact Us

Shruti Thakur

[email protected]

+14699457679

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP